Literature DB >> 28263854

Method for rapid optimization of recombinant GPCR protein expression and stability using virus-like particles.

Thao T Ho1, Jasmine T Nguyen2, Juping Liu3, Pawel Stanczak4, Aaron A Thompson5, Yingzhuo G Yan6, Jasmine Chen7, Charles K Allerston8, Charles L Dillard9, Hao Xu10, Nicholas J Shoger11, Jill S Cameron12, Mark E Massari13, Kathleen Aertgeerts14.   

Abstract

Recent innovative approaches to stabilize and crystallize GPCRs have resulted in an unprecedented breakthrough in GPCR crystal structures as well as application of the purified receptor protein in biophysical and biochemical ligand binding assays. However, the protein optimization process to enable these technologies is lengthy and requires iterative overexpression, solubilization, purification and functional analysis of tens to hundreds of protein variants. Here, we report a new and versatile method to screen in parallel hundreds of GPCR variants in HEK293 produced virus-like particles (VLPs) for protein yield, stability, functionality and ligand binding. This approach reduces the time and resources during GPCR construct optimization by eliminating lengthy protein solubilization and purification steps and by its adaptability to many binding assay formats (label or label-free detection). We exemplified the robustness of our VLP method by screening 210 GALR3-VLP variants in a radiometric agonist-based binding assay and a subset of 88 variants in a label-free antagonist-based assay. The resulting GALR3 agonist or antagonist stabilizing variants were then further used for recombinant protein expression in transfected insect cells. The final purified protein variants were successfully immobilized on a biosensor chip and used in a surface plasmon resonance binding assay.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GPCR protein stabilization; GPCR recombinant protein expression; Membrane protein; Protein engineering; Virus-like particles

Mesh:

Substances:

Year:  2017        PMID: 28263854     DOI: 10.1016/j.pep.2017.03.002

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

1.  Dataset on Galanin Receptor 3 mutants that improve recombinant receptor expression and stability in an agonist and antagonist bound form.

Authors:  Thao T Ho; Jasmine T Nguyen; Juping Liu; Pawel Stanczak; Aaron A Thompson; Yingzhuo G Yan; Jasmine Chen; Charles K Allerston; Charles L Dillard; Hao Xu; Nicholas J Shoger; Jill S Cameron; Mark E Massari; Kathleen Aertgeerts
Journal:  Data Brief       Date:  2017-05-04

2.  Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies.

Authors:  Martin J Scott; Amanda Jowett; Martin Orecchia; Peter Ertl; Larissa Ouro-Gnao; Julia Ticehurst; David Gower; John Yates; Katie Poulton; Carol Harris; Michael J Mullin; Kathrine J Smith; Alan P Lewis; Nick Barton; Michael L Washburn; Ruud de Wildt
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 3.  Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies.

Authors:  Man-Seok Ju; Sang Taek Jung
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.